<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01433614</url>
  </required_header>
  <id_info>
    <org_study_id>TEX trial</org_study_id>
    <nct_id>NCT01433614</nct_id>
  </id_info>
  <brief_title>Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer</brief_title>
  <acronym>TEX</acronym>
  <official_title>Treatment With the Combination of Epirubicin and Paclitaxel Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer. A Multicenter, Randomized Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Hatschek</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anthracycline-taxane regimens are effective means of postponing progression in metastatic
      breast cancer. It is yet unclear whether addition of capecitabine to this combination
      improves the treatment outcome.

      Patients with advanced breast cancer are randomized to first-line chemotherapy with a
      combination of epirubicin (Farmorubicin®) and paclitaxel (Taxol®) alone (ET) or in
      combination with capecitabine (Xeloda®, TEX). Starting doses for ET are epirubicin 75 mg/m2
      plus paclitaxel 175 mg/m2, and for TEX epirubicin 75mg/m2, paclitaxel 155 mg/m2, and
      capecitabine 825 mg/m2 BID for 14 days. Subsequently, doses are tailored related to side
      effects.

      Primary endpoint is progression-free survival (PFS); secondary endpoints are overall survival
      (OS), time to treatment failure (TTF), objective response (OR), safety and quality of life
      (QoL).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>From date of randomisation until date of first radiolocically documented progression or death from any cause, whichever comes first up to 78 months</time_frame>
    <description>Time to progression comparing treatment with ET vs. TEX in patients with advanced breast cancer. Evaluation every 9 weeks during treatment until progression as long as study treatment was given, and every 12 weeks until date of progression, if treatment was disrupted for any other reason. Patients in the state of persistent complete response after primary completion date were reported only upon date of progression or death up to 78 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>From date of randomization until date of treatment disruption for any reason up to 78 months</time_frame>
    <description>Time on treatment irrespective of reason for disruption (toxicity, patients wish)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Every 9 weeks during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from randomisation until date of death up to 78 months</time_frame>
    <description>Date and cause of death reported yearly during the ongoing trial, up to 78 months after primary completion date only on the occasion of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Continuously during treatment and until 2 months after termination</time_frame>
    <description>All side effects which appear during treatment are reported and graded according CTC v.2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline, 2, 4, 6 and 9 months</time_frame>
    <description>Measured at five points during nine months from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor biological data related to treatment</measure>
    <time_frame>Within two weeks before start of treatment</time_frame>
    <description>Fine needle aspirates from metastases</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">304</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Epirubicin + paclitaxel (Taxol)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epirubicin 75mg/m2 i.v., paclitaxel 175 mg/m2 i.v. on day 1 every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel + epirubicin + capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 155 mg/m2 i.v., epirubicin 75 mg/m2 i.v day 1, capecitabine 1650 mg/m2 p.o. on days 1-14 every 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>75 mg/m2 i.v. every 3 weeks, both study arms</description>
    <arm_group_label>Epirubicin + paclitaxel (Taxol)</arm_group_label>
    <arm_group_label>Paclitaxel + epirubicin + capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>175 mg/m2 i.v., every 3 weeks study arm A 155 mg/m2 i.v., every 3 weeks study arm B</description>
    <arm_group_label>Epirubicin + paclitaxel (Taxol)</arm_group_label>
    <arm_group_label>Paclitaxel + epirubicin + capecitabine</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1650 mg/m2 p.o. days 1-14 every 3 weeks study arm B</description>
    <arm_group_label>Paclitaxel + epirubicin + capecitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Morphologically proven breast carcinoma

          -  Written patient consent must be obtained

          -  Measurable disease (i.e. at least one lesion that can be accurately measured in at
             least one dimension as ≥20 mm by conventional techniques, or as ≥10 mm by spiral CT
             scan) as defined in section 8.

          -  Lytic and blastic bone metastases as only site of recurrence are allowed

          -  Age 18 years or older

          -  ECOG performance status 0-2

          -  Life expectancy of at least three months

          -  Adequate cardiac functions

          -  Adequate hematological, renal and hepatic functions

          -  Patient must be accessible for treatment and follow-up.

        Exclusion Criteria:

          -  Treatment-free interval less than one year, if previous adjuvant, neoadjuvant or after
             radically treated locoregional recurrence given regimen contained anthracycline,
             taxane or capecitabine. This limitation does not apply for regimens containing other
             than the drugs mentioned

          -  During adjuvant treatment obtained cumulative doses exceeding 375 mg/m2 for
             doxorubicin, or 550 mg/m2 for epirubicin, abnormal ECG or reduced cardiac function
             measured by left ventricular ejection fraction (LVEF).

          -  Indication for the use of trastuzumab (Herceptin) as first-line treatment in patients
             with tumor overexpressing c-erbB2.

          -  Any previous chemotherapy for metastatic disease, except for radically treated
             locoregional relapse

          -  Neoplasm other than breast carcinoma, except for non-melanoma skin cancer or
             curatively treated carcinoma in situ of the cervix, diagnosed during the past five
             years

          -  Pregnancy or lactation

          -  Known brain metastases

          -  History of atrial or ventricular arrhythmias and/or congestive heart failure, even if
             medically controlled. History of clinical and electrocardiographically documented
             myocardial infarction

          -  Preexisting motor or sensory neuropathy ≥ grade 2 according to NCI CTC 2.0 criteria
             (severe paresthesia and/or mild weakness, or worse)

          -  Severe hepatic or renal impairment (for capecitabine: calculated creatinine clearance
             below 30 ml/min; for calculation, see p. 5.1.4) not allowing for adequate use of the
             proposed regimens

          -  History of known dihydropyrimidine dehydrogenase (DPD) deficiency (severe reaction on
             previous treatment with fluorouracil, e.g experience of mucositis, hand-foot syndrome,
             or diarrhea)

          -  Active infection or other serious underlying medical condition which would impair the
             ability of the patient to receive protocol treatment, including prior allergic
             reactions to drugs containing cremophor, such as teniposide, cyclosporin or vitamin K

          -  Dementia or significantly altered mental status that would prohibit the understanding
             and giving of informed consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Hatschek, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsingborg Gen. Hospital</name>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalmar Central Hospital</name>
      <address>
        <city>Kalmar</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karlstad Gen. Hospital</name>
      <address>
        <city>Karlstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malmö General University Hospital</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sundsvall Gen. Hospital</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norrland University Hospital</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Svensson H, Brandberg Y, Einbeigi Z, Hatschek T, Ahlberg K. Psychological reactions to progression of metastatic breast cancer--an interview study. Cancer Nurs. 2009 Jan-Feb;32(1):55-63.</citation>
    <PMID>19104202</PMID>
  </results_reference>
  <results_reference>
    <citation>Svensson H, Einbeigi Z, Johansson H, Hatschek T, Brandberg Y. Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine). Breast Cancer Res Treat. 2010 Oct;123(3):785-93. doi: 10.1007/s10549-010-1084-8. Epub 2010 Aug 3.</citation>
    <PMID>20680680</PMID>
  </results_reference>
  <results_reference>
    <citation>Svensson H, Hatschek T, Johansson H, Einbeigi Z, Brandberg Y. Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer. Med Oncol. 2012 Jun;29(2):432-8. doi: 10.1007/s12032-011-9844-9. Epub 2011 Feb 6.</citation>
    <PMID>21298494</PMID>
  </results_reference>
  <results_reference>
    <citation>Hatschek T, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B, Lindh B, Loman N, Malmberg M, Rotstein S, Söderberg M, Sundquist M, Walz TM, Hellström M, Svensson H, Aström G, Brandberg Y, Carstensen J, Fernö M, Bergh J. Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial. Breast Cancer Res Treat. 2012 Feb;131(3):939-47. doi: 10.1007/s10549-011-1880-9. Epub 2011 Nov 18.</citation>
    <PMID>22094937</PMID>
  </results_reference>
  <results_reference>
    <citation>Suzuki C, Blomqvist L, Hatschek T, Carlsson L, Einbeigi Z, Linderholm B, Lindh B, Loman N, Malmberg M, Rotstein S, Söderberg M, Sundqvist M, Walz TM, Aström G, Fujii H, Jacobsson H, Glimelius B. Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy. Med Oncol. 2013 Mar;30(1):415. doi: 10.1007/s12032-012-0415-5. Epub 2013 Jan 16.</citation>
    <PMID>23322522</PMID>
  </results_reference>
  <results_reference>
    <citation>Bjöhle J, Bergqvist J, Gronowitz JS, Johansson H, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Söderberg M, Sundquist M, Walz TM, Fernö M, Bergh J, Hatschek T. Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial. Breast Cancer Res Treat. 2013 Jun;139(3):751-8. doi: 10.1007/s10549-013-2579-x. Epub 2013 Jun 5.</citation>
    <PMID>23736998</PMID>
  </results_reference>
  <results_reference>
    <citation>Tobin NP, Harrell JC, Lövrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Walz T, Fernö M, Perou CM, Bergh J, Hatschek T, Lindström LS; TEX Trialists Group. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Ann Oncol. 2015 Jan;26(1):81-8. doi: 10.1093/annonc/mdu498. Epub 2014 Oct 31.</citation>
    <PMID>25361981</PMID>
  </results_reference>
  <results_reference>
    <citation>Kimbung S, Kovács A, Bendahl PO, Malmström P, Fernö M, Hatschek T, Hedenfalk I. Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences. Mol Oncol. 2014 Feb;8(1):119-28. doi: 10.1016/j.molonc.2013.10.002. Epub 2013 Oct 14.</citation>
    <PMID>24287398</PMID>
  </results_reference>
  <results_reference>
    <citation>Kimbung S, Johansson I, Danielsson A, Veerla S, Egyhazi Brage S, Frostvik Stolt M, Skoog L, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B, Loman N, Malmström PO, Söderberg M, Walz TM, Fernö M, Hatschek T, Hedenfalk I; TEX study group. Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer. Clin Cancer Res. 2016 Jan 1;22(1):146-57. doi: 10.1158/1078-0432.CCR-15-0487. Epub 2015 Aug 14.</citation>
    <PMID>26276891</PMID>
  </results_reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2011</study_first_submitted>
  <study_first_submitted_qc>September 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2011</study_first_posted>
  <last_update_submitted>September 16, 2015</last_update_submitted>
  <last_update_submitted_qc>September 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Thomas Hatschek</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 7, 2015</submitted>
    <returned>November 6, 2015</returned>
    <submitted>November 6, 2015</submitted>
    <returned>December 14, 2015</returned>
    <submitted>February 14, 2016</submitted>
    <returned>March 10, 2016</returned>
    <submitted>November 2, 2016</submitted>
    <returned>December 30, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

